Prospera Energy Utilizes Strong Balance Sheet to Capitalize 2023 Development Plan Accelerating Production Growth
CALGARY, Alberta, March 03, 2023 (GLOBE NEWSWIRE) -- Prospera Energy Inc.PEI: TSX-V; OF6A: FRA, OTC: GXRFF
Prospera is structured to be well-capitalized in 2023 to fund the capital development program to capture the significant remaining reserves in place. PEI total capitalization ($15 million) includes strategic debt offering below, combined with substantial warrant exercise program of up to $10 million CAD in 2023 plus positive cash flow from operations.
PEI hereby announces that it is undertaking a non-brokered private placement debt financing. A total of up to $5,000,000 will be raised offering holders’ interest of 8% per annum, with interest payments to be made quarterly for a term of 2 years. In addition to interest, holders will receive one common share for each dollar of principal advanced, at the time of investment. The company already has received a subscription for $2,500,000 towards this offering.
Debt Term Sheet
|Issuer:||Prospera Energy Inc. (“Prospera” or the “Corporation”).|
|Issue:||Non-brokered offering (the "Offering") of units ("Units"). Each Unit will consist of (I) one-thousand common shares of the Corporation (issued at closing); and (ii) one 8% 2-year promissory note in the principal amount of $1,000.|
|Issue Price:||$1,000 per Unit.|
|Offering Amount:||Up to $5,000,000.|
|Term:||Principal repaid at the end of 2 years.|
|Closing Date:||Anticipated for March 31, 2023.|
|Underlying Shares:||Common shares of the Company listed on the TSX Venture Exchange under the symbol PEI (the “Common Shares”).|
|Use of Proceeds:||Prospera intends to use the net proceeds of the Offering for infrastructure upgrades to accommodate further production growth, well development capital, well abandonment costs, ongoing ESG initiatives and general working capital.|
|Interest:||8% interest per annum, calculated and paid quarterly in cash starting after the 2nd quarter (interest in the first quarter is compounded).|
|Minimum Investment:||Notes will be issued in denominations of $1,000, subject to a minimum investment of $10,000.|
|Offering Basis:||Non- brokered private placement offering.|
|Finders Fees:||The Corporation may pay qualified finders a fee of 3% cash and 3% warrants.|
Prospera’s strategic evaluation suggests equity values are not appropriately accounting for the future potential of its asset values (i.e., 350 million+ barrels in place). The company is focused on minimal dilution financing options moving forward and if fully subscribed, this debt financing would only represent less than 2% equity dilution.
Prospera intends to use the net proceeds of the debt offering, cashflow from operations, and substantial capital raised from warrant exercises, to accelerate the company’s planned drill program this spring, summer, and fall to further production growth. There are significant economic advantages in drilling during the upcoming summertime.
Parties interested in participating in this debt offering should contact the company immediately. Insiders may participate in this offering. Prospera is relying upon exemptions contained in MI61-101 from the requirements for an independent evaluation and minority shareholder approval. This offering is subject to approval from the TSX Venture exchange.
Prospera is a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in Western Canada. Prospera will utilize experience and knowledge to develop, acquire, and drill assets with potential for primary and secondary recovery.
For Further Information:
Shawn Mehler, PR
This news release contains forward-looking statements relating to the future operations of the Corporation and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will,” “may,” “should,” “anticipate,” “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding future plans and objectives of the Corporation, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
Although Prospera believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Prospera can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, risks associated with the oil and gas industry in general (e.g., operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of reserve estimates; the uncertainty of estimates and projections relating to production, costs and expenses, and health, safety and environmental risks), commodity price and exchange rate fluctuations and uncertainties resulting from potential delays or changes in plans with respect to exploration or development projects or capital expenditures.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Prospera. As a result, Prospera cannot guarantee that any forward-looking statement will materialize, and the reader is cautioned not to place undue reliance on any forward- looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and Prospera does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by Canadian securities law.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS23.3.2023 01:31:57 CET | Press release
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidence sufficient to conclude that a reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict clinical benefit of tofersen for treatment of patients with SOD1-ALS?” the Committee voted unanimously yes (9 yes to 0 no), for consideration of a potential accelerated approval. On the second question, “Does the clinical data from the placebo-controlled study and available long-term extension study results, with additional supporting res
GN Store Nord announces change to the Board of Directors22.3.2023 22:22:29 CET | Press release
Due to sudden serious health issues in the family, Montserrat Maresch Pascual has decided to step down from the Board of Directors of GN Store Nord A/S. The Chairmanship assesses that the remaining five members of the Board possess all the relevant competencies and experience to govern the company. Consequently, GN’s Board of Directors as of today consists of Jukka Pekka Pertola (Chair), Klaus Holse (Deputy chair), Anette Weber, Hélène Barnekow, Ronica Wang, and members elected by the employees: Leo Larsen, Cathrin Inge Hansen, and Claus Holmbeck-Madsen. For further information, please contact: Investor Relations Anne Sofie Staunsbæk Veyhe +45 45 75 85 06 Rune Sandager +45 45 75 92 57 Media Relations Steen Frentz Laursen +45 20 65 34 20 About GN GN facilitates communication between people through intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our passion for innovation, we leverage technologies to deliver unique user experiences that bring pe
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 202222.3.2023 22:05:00 CET | Press release
ERYTECH Provides Business and Financial Update for the Fourth Quarterand Full Year 2022 Combination with Pherecydesannounced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteria Deep restructuring implemented; team size reduced by approximately 75% since start of 2022Cash and cash equivalents of €38.8million ($41.5 million) at the end of December 2022 Cambridge, MA (U.S.) and Lyon (France),March 22, 2023– ERYTECH Pharma (Nasdaq & Euronext: ERYP),aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial updatefor thefourth quarterand full year of2022. “After the disappointing results of our Phase 3 trial in pancreatic cancer, we have pursued during 2022 a consistent strategy to maximize the remaining value for our shareholders through strategic partnering. We sold our US manufacturing site, sharply
Hvidbjerg Banks ordinære generalforsamling den 22. marts 202322.3.2023 21:48:49 CET | pressemeddelelse
Formand Henrik H. Galsgaard udpegede advokat Rasmus Kronborg, Thisted til dirigent i henhold til vedtægternes § 9. Rasmus Kronborg takkede for valget og konstaterede, at generalforsamlingen var korrekt indvarslet og beslutningsdygtig med hensyn til generalforsamlingens dagsorden, som blev gennemgået. Dagsordenens punkt 1: Formand Henrik H. Galsgaard aflagde på bestyrelsens vegne mundtlig beretning om bankens virksomhed i det forløbne år. På grund af kommende kapitalkrav forventes der ikke udbetalt udbytte i de kommende år. Der var ikke kommet bemærkninger eller spørgsmål, hvorefter dirigenten konstaterede, at beretningen var taget til efterretning. Dagsordenens punkt 2 og 3: Bankdirektør Jens Odgaard fremlagde årsrapporten til godkendelse og årsrapporten blev godkendt. Årets resultat t.kr. 25.172 blev vedtaget overført således: Udbytte 0 Rente hybrid kernekapital 975 Henlagt til egenkapitalen 24.197 I alt anvendt 25.172 Dagsordenens punkt 4: Bestyrelsesformand Henrik H. Galsgaard freml
CNH Industrial: Periodic Report on $300 Million Buyback Program. Completion of Second $50 million tranche and launch of Third $50 million tranche22.3.2023 21:30:00 CET | Press release
London, March 22, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that it has completed the second tranche of its $50 million share buyback (the “Second Tranche”) in the framework of its $300 million common share buyback program with the transaction described in the table below. The transaction, completed on March 13, 2023, reported in aggregate, was based on automatic orders placed with the Company’s broker (who made its trading decisions as to the timing of the purchases independently of the Company based on instructions given before the commencement of the Company’s closed period under the applicable regulations). After the purchases announced today and considering those previously executed under the Second Tranche, the total invested amount is approximately €46,863,453.43 ($49,999,997.50) for a total amount of 3,065,368 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (**) exclu